| Dr John T Whalen, MD | |
|
121 Everett Rd, Albany, NY 12205-1474 | |
| (518) 489-2663 | |
| (518) 689-3881 |
| Full Name | Dr John T Whalen |
|---|---|
| Gender | Male |
| Speciality | Orthopedic Surgery |
| Experience | 35 Years |
| Location | 121 Everett Rd, Albany, New York |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1720055130 | NPI | - | NPPES |
| 190181 | Other | NY | NY LICENSE |
| 01586507 | Medicaid | NY |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207XS0117X | Orthopaedic Surgery - Orthopaedic Surgery Of The Spine | 190181 (New York) | Secondary |
| 207X00000X | Orthopaedic Surgery | 190181 (New York) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Eddy Visiting Nurse & Rehab Association | Troy, NY | Home health agency |
| Samaritan Hospital | Troy, NY | Hospital |
| Sunnyview Hospital And Rehabilitation Center | Schenectady, NY | Hospital |
| St Peter's Hospital | Albany, NY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Orthopedicsny, Llp | 6901898170 | 104 |
News Archive
A Washington Post editorial calles anti-gay legislation currently under consideration in Uganda "an atrocity." The authors of the editorial write that under the legislation, "anyone convicted of 'aggravated homosexuality,' which could mean someone who is HIV-positive and is intimate with another person of the same sex, could 'suffer death.'"
DURECT Corporation today announced the successful completion of a Phase 1 clinical trial with an injectable formulation of DUR-928 intended for acute use indications. DUR-928 is an endogenous, small-molecule, new chemical entity (NCE), which may have broad applicability in metabolic diseases such as nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), and in acute organ injuries such as acute kidney injury (AKI).
Amorcyte, LLC, a NeoStem, Inc. company today announces the enrollment of the first patient in the Amorcyte PreSERVE Phase 2 trial for acute myocardial infarction.
AbleNet, Inc. announces the agreement with Madentec Limited of Edmonton, Alberta, Canada for the exclusive global rights to manufacture and sell their entire line of assistive technology solutions. This adds a broad portfolio of proven devices to the AbleNet computer access products. Madentec will continue to own the products and provide engineering development support, which has been their core strength.
Genetic mutations aren't the only thing that can keep a protein called PTEN from doing its tumor-suppressing job. Johns Hopkins researchers have now discovered that four small chemical tags attached (reversibly) to the protein's tail can have the same effect, and they say their finding may offer a novel path for drug design to keep PTEN working.
› Verified 2 days ago
| Entity Name | Orthopedicsny, Llp |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1568415412 PECOS PAC ID: 6901898170 Enrollment ID: O20040330001750 |
News Archive
A Washington Post editorial calles anti-gay legislation currently under consideration in Uganda "an atrocity." The authors of the editorial write that under the legislation, "anyone convicted of 'aggravated homosexuality,' which could mean someone who is HIV-positive and is intimate with another person of the same sex, could 'suffer death.'"
DURECT Corporation today announced the successful completion of a Phase 1 clinical trial with an injectable formulation of DUR-928 intended for acute use indications. DUR-928 is an endogenous, small-molecule, new chemical entity (NCE), which may have broad applicability in metabolic diseases such as nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), and in acute organ injuries such as acute kidney injury (AKI).
Amorcyte, LLC, a NeoStem, Inc. company today announces the enrollment of the first patient in the Amorcyte PreSERVE Phase 2 trial for acute myocardial infarction.
AbleNet, Inc. announces the agreement with Madentec Limited of Edmonton, Alberta, Canada for the exclusive global rights to manufacture and sell their entire line of assistive technology solutions. This adds a broad portfolio of proven devices to the AbleNet computer access products. Madentec will continue to own the products and provide engineering development support, which has been their core strength.
Genetic mutations aren't the only thing that can keep a protein called PTEN from doing its tumor-suppressing job. Johns Hopkins researchers have now discovered that four small chemical tags attached (reversibly) to the protein's tail can have the same effect, and they say their finding may offer a novel path for drug design to keep PTEN working.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr John T Whalen, MD 121 Everett Rd, Albany, NY 12205-1474 Ph: (518) 489-2663 | Dr John T Whalen, MD 121 Everett Rd, Albany, NY 12205-1474 Ph: (518) 489-2663 |
News Archive
A Washington Post editorial calles anti-gay legislation currently under consideration in Uganda "an atrocity." The authors of the editorial write that under the legislation, "anyone convicted of 'aggravated homosexuality,' which could mean someone who is HIV-positive and is intimate with another person of the same sex, could 'suffer death.'"
DURECT Corporation today announced the successful completion of a Phase 1 clinical trial with an injectable formulation of DUR-928 intended for acute use indications. DUR-928 is an endogenous, small-molecule, new chemical entity (NCE), which may have broad applicability in metabolic diseases such as nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), and in acute organ injuries such as acute kidney injury (AKI).
Amorcyte, LLC, a NeoStem, Inc. company today announces the enrollment of the first patient in the Amorcyte PreSERVE Phase 2 trial for acute myocardial infarction.
AbleNet, Inc. announces the agreement with Madentec Limited of Edmonton, Alberta, Canada for the exclusive global rights to manufacture and sell their entire line of assistive technology solutions. This adds a broad portfolio of proven devices to the AbleNet computer access products. Madentec will continue to own the products and provide engineering development support, which has been their core strength.
Genetic mutations aren't the only thing that can keep a protein called PTEN from doing its tumor-suppressing job. Johns Hopkins researchers have now discovered that four small chemical tags attached (reversibly) to the protein's tail can have the same effect, and they say their finding may offer a novel path for drug design to keep PTEN working.
› Verified 2 days ago
George S Zanaros, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 1367 Washington Ave, Suite 200, Albany, NY 12206 Phone: 518-489-2666 Fax: 518-489-5933 | |
Kaushik Bagchi, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 1367 Washington Ave, Suite 200, Albany, NY 12206 Phone: 518-489-2666 Fax: 518-489-2666 | |
Dr. Christopher De Camp, M.D. Orthopedic Surgery Medicare: Medicare Enrolled Practice Location: 121 Everett Rd, Albany, NY 12205 Phone: 518-453-9088 Fax: 518-689-6111 | |
Dr. Justin Tyler Zaremba, MD Orthopedic Surgery Medicare: Not Enrolled in Medicare Practice Location: 43 New Scotland Ave, Albany, NY 12208 Phone: 518-453-3079 | |
Jeffrey Lozman, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 1367 Washington Ave, Suite 200, Albany, NY 12206 Phone: 518-489-2666 Fax: 518-489-5933 | |
Dr. Imran Akhtar, D.O. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 121 Everett Rd, Albany, NY 12205 Phone: 518-489-2663 Fax: 518-689-3881 | |
Dr. Leonard E Goldstock, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 121 Everett Rd, Albany, NY 12205 Phone: 518-453-9088 Fax: 518-689-6111 |